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UPDATE on EMERGENCY CONTRACEPTION  
Precis: 
Emergency contraceptive options include combined and progestin-only pills, ulipristal 
acetate, and the copper intrauterine device. 
 
Abstract: 
Emergency contraception (EC) is any method used after sexual intercourse to prevent 
pregnancy. This article provides an overview of the history of EC methods and 
describes the current availability of oral and intrauterine EC. Oral forms include the 
Yuzpe regimen (combining ethinyl estradiol and levonorgestrel), levonorgestrel–only 
pills, and ulipristal acetate, which is a new emergency contraceptive drug recently 
approved by the US Food and Drug Administration. The copper T-380A intrauterine 
device can also be used for EC. Information about dosing, timing, access, and other 
considerations in the provision of EC is covered. Clinicians should be aware of all 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript 
UPDATE on EMERGENCY CONTRACEPTION 
 INTRODUCTION 
Emergency contraception (EC) is any contraceptive method used after sexual 
intercourse to prevent pregnancy. References to the concept of postcoital contraception 
date back to ancient times, with common instructions being to sneeze, jump backwards, 
and otherwise attempt to expel semen immediately after sexual intercourse 1-3. Modern 
clinicians have undoubtedly heard other myths about ways to prevent pregnancy after 
sex. Indeed, one such myth, douching with a carbonated beverage, produced published 
laboratory-based research to evaluate its presumed effectiveness 4-6. The beginnings of 
modern effective EC however date to the 1920s, when veterinarians administered high-
dose estrogens to animals to prevent pregnancies from unintended mating 7. Possibly 
the first documented use in humans was in mid 1960s when physicians in the 
Netherlands gave estrogens to a 13-year-old girl who had been raped.3  
Emergency contraception should be offered to every woman who reports 
unprotected intercourse, whether voluntary or forced.  Currently available options in the 
United States are listed in Table 1. The purpose of this article is to update clinicians 
about options for and management of the drugs and devices available in the United 
States for emergency contraception.  
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Abbreviations: MEC, Medical Eligibility Criteria for Contraceptive Use; STI, sexually transmitted infection  
Sources: Centers for Disease Control and Prevention 46 , Food and Drug Administration 22 ,Glasier 45 ,Trussell51 , World Health Organization 62 , Wu 
59 ,  
a US MEC Categories: 
Category 1: a condition for which there is no restriction 
Category 2: a condition for which the advantages of using the method generally outweigh the theoretical or proven risks 
Category 3: a condition for which the theoretical or proven risks usually outweigh the advantages of using the method 
Category 4: a condition that represents an unacceptable health risk if the contraceptive method is used. 
b A single dose has been shown to be as effective as 2 doses, although some package labeling continues to state it should be taken in 2 doses. 
c Rates taken from clinical trials that compared levonorgestrel and ulipristal acetate and calculated actual risk, not relative risk. 
d This rate was taken from a single-arm trial that evaluated the effectiveness of ulipristal acetate beyond 72 hours. 
e These regimens are not the first choice, due to associated rates of nausea and vomiting. If these are the only option available for a woman, the 
number of pills and dosing from 19 different branded combined oral contraceptive products is available from the Princeton University Office of 
Population Research and Association of Reproductive Health Professionals and can be accessed at 
http://ec.princeton.edu/questions/dose.html.) 
 
f No studies have evaluated effectiveness beyond 72 hours. 
 
The oral form of EC, the so-called “morning after pill”, is the most commonly used EC 
method and can be taken at any time in the first 3 to 5 days after unprotected sex to 
prevent pregnancy (not just “the morning after”). 
Formulations for Emergency Contraception 
Combined Estrogen-Progestin Formulations 
In the mid to later 20th century, women in need of EC typically received either 
high-dose diethylstilbestrol, conjugated estrogens, or ethinyl estradiol, administered 
over several days after unprotected sex. These regimens were replaced in the 1980s by 
the so-called Yuzpe regimen, named for the Canadian physician who first described it 8. 
This regimen involved 2 doses of oral contraceptive pills  containing both ethinyl 
estradiol and norgestrel; each dose contained 200 mcg of ethinyl estradiol and 1.0 mg 
of norgestrel. In 1997, the US Food and Drug Administration (FDA) concluded that the 
Yuzpe regimen was safe and effective for off-label use as postcoital EC 9.  At the time, 6 
branded hormonal oral contraceptive products were listed in instructions for providing 
an appropriate dose of the 2 hormones for EC. In 1998, the FDA approved a dedicated 
product (Preven) that packaged 4 pills as an emergency contraception kit 10.  Preven 
was discontinued in May 2004. Although use of combined EC  has largely been 
replaced by the single hormone products discussed in the next sections, current 
authoritative EC resources continue to list 19 branded oral contraceptives that can be 
used to provide an EC dose if the preferred products are not available. 11 Although all of 
the oral contraceptive regimens currently recommended for EC contain ethinyl estradiol 
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has suggested that a combination of ethinyl estradiol and norethindrone may work as 
well 12. 
Progestin-only Formulations 
In the 1970s, several studies evaluated high-dose progestins used peri- and 
postcoitally as an ongoing primary contraceptive method, but interest waned due to the 
cycle irregularities that accompanied continued or frequent use of the method 13-16. 
However, this experience, along with the common side effect of nausea and vomiting 
with use of combined EC regimens containing ethinyl estradiol, led to consideration of 
progestin-only treatments as EC. Levonorgestrel-only EC was evaluated in a number of 
studies in the 1990s, including a large trial by the World Health Organization (WHO), 
that compared this progestin-only regimen to the Yuzpe regimen containing both a 
progestin and ethinyl estradiol. These studies demonstrated the effectiveness and lower 
side effect rates of the levonorgestrel-only dosing. 17,18 Following these findings, the 
combined EC product was gradually withdrawn from the market in favor of 
levonorgestrel-only products. As previously noted, authoritative resources still provide 
the correct dosing of the Yuzpe combined EC regimen for those unable to access 
progestin-only products. 11 
The original branded levonorgestrel –only product (Plan B, approved in 1999) 
contained 2 doses of 0.75 mg of levonorgestrel taken 12 hours apart. A 2002 WHO 
study 19 found that progestin-only EC can be taken in a single dose of 1.5 mg total; one 
current branded product offers this single dose (Plan B One Step, approved in 2009, 
which has replaced the original branded product). The other branded product retains the 
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doses can be taken at once. The current FDA-approved labeling for the branded 
products states that the dose should be taken within 72 hours of unprotected sex. 
However, data from the WHO study also suggested that progestin-only oral EC can be 
taken up to 120 hours after intercourse and still maintain some effectiveness, although 
there is a decline in effectiveness with delay.19  
Emergency contraception dosing with levonorgestrel provides a higher dose (1.5 
mg) than is typical in progestin-only daily contraceptives; one would have to take 40 
separate tablets of a norgestrel progestin-only contraceptive pill to approximate the 
single-dose emergency contraceptive pill 11. The dose is also higher than the daily dose 
one would get in hormonal contraceptives that contain levonorgestrel;  the Yuzpe 
regimen dosing of the various combined EC products requires taking anywhere from 4 
to 10 pills to achieve a total of 1.0 to 1.2 mg of levonorgestrel in 2 doses.11 The branded 
levonorgestrel-only emergency contraceptive products contain a total of 1.5 mg.  
Antiprogestin Formulations 
 Antiprogestins are progesterone receptor antagonists, or progesterone receptor 
modulators, that counteract the effects of progesterone, which is a critical component of 
the events that lead to fertilization and the establishment of pregnancy. Mifepristone is 
an antiprogestin and highly effective as a postcoital emergency contraceptive. A single 
dose of mifepristone in a range of 25 to 50 mg is more effective for EC than 
levonorgestrel regimens, and can be used up to 120 hours after unprotected intercourse 
20. There are fewer side effects than observed with other methods. Because 
mifepristone is a component of the medication regimen to induce abortion, there are 
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use as an emergency contraceptive in the United States (it is available as an 
emergency contraceptive in China and Russia). Note that the FDA-approved dose of 
mifepristone for medication abortion is 600mg; dosing for EC purposes is less than 10% 
of this and does not function as an abortifacient.21 
 A second generation antiprogestin, ulipristal acetate (UPA), has been studied as 
an EC agent and was approved for this use in Europe in 2009 and by the FDA in 2010 
22. This is a new drug with limited post-marketing experience and is available only by 
prescription, as a 30 mg single oral dose (brand name ella). Animal studies 
demonstrated that UPA and mifepristone are roughly equipotent; thus this drug will not 
function as an abortifacient at the approved dose.23 
Several comparative clinical studies with large populations provided the efficacy 
and safety data that led to approval of the drug.  An early randomized trial of nearly 
1700 women compared a 50 mg dose of UPA (note that the current FDA-approved 
dose is 30 mg) to the 1.5 mg EC dose of levonorgestrel. The pregnancy rate in the UPA 
group was 0.9% (95% confidence interval [CI], 0.2%-1.6%) as compared to 1.7% in the 
levonorgestrel group (95% CI, 0.8%-2.6%) 24. Another study with more than 2200 
women used a 30 mg oral dose of UPA and compared outcomes to 1.5 mg single dose 
of levonorgestrel. In the evaluable UPA sample, the pregnancy rate was 1.8% (95% CI, 
1.0%-3.0%), compared to 2.6% (95% CI, 1.7%-3.9%) in the levonorgestrel group. In this 
study there were 203 women who took EC after 72 hours but within 120 hours of 
unprotected intercourse. There were 3 pregnancies in the delayed dosing group, and all 
were in the levonorgestrel arm.25 An observational prospective study evaluated efficacy 
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the efficacy of levonorgestrel begins to wane) up to 120 hours. There were 1241 women 
in the evaluable sample, and the overall pregnancy rate was 2.6% (95% CI, 1.4%-
3.1%). The pregnancy rate was 2.3% when dosing occurred between 48 and 72 hours, 
2.1% when dosing occurred between 72 and 96 hours, and 1.3% from 96 to 120 hours 
26. In summary, the available research demonstrates that UPA is an effective 
emergency contraceptive, with lower failure rates than levonorgestrel and effectiveness 
up to 120 hours. 
Other Drugs as Emergency Contraceptives 
 Several animal and human studies suggest that cyclooxygenase-2 (COX-2) 
inhibitors can prevent or delay follicular rupture. Meloxicam (Mobic), given as 30 mg a 
day for 5 consecutive days, produced dysfunctional ovulation in half of 22 women 
treated during the late follicular phase (when  a leading follicle reached a size of 18 mm) 
27. Larger clinical studies to assess effectiveness and risk are needed. Currently, use of 
meloxicam as EC is investigational and should not be recommended in clinical practice. 
Meloxicam carries a black box warning about cardiovascular and gastrointestinal risks 
and is currently approved by the FDA only for the treatment of osteoarthritis and 
rheumatoid arthritis.28 Other FDA-approved EC regimens do not carry such risks. 
Mechanism of Action of Oral Emergency Contraception Products 
The generally accepted mechanisms of action for progestin-only EC, as well as 
for the combined EC products, include inhibition of ovulation, disruption of follicular 
development, and interference with the maturation of the corpus luteum. When 
levonorgestrel EC is taken prior to the day before a woman’s LH surge, it suppresses 
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the LH surge, it blunts or delays the surge and renders the ova resistant to 
fertilization.29-34 
Some have theorized that levonorgestrel EC produces histological/biochemical 
alterations of the endometrium, thereby impairing its receptivity to implantation. More 
recent studies have demonstrated little to no effect on the endometrium.35,36 Other 
suggested mechanisms of action include alteration of sperm or egg transport, 
interference with fertilization, and/or cervical mucus changes, but none of these has 
been verified by clinical data. There is no evidence that levonorgestrel EC can interrupt 
an established pregnancy that has already implanted in the uterine lining.37,38 
As is true of levonorgestrel regimens, the likely primary mechanism of action of 
ulipristal acetate is inhibition or delay of ovulation. Studies have shown that when this 
drug is administered before the onset of the LH surge, there is no follicular rupture 
evident for 5 days after treatment. When administered after the onset of the surge, but 
before the peak, 79% of women treated showed no follicular rupture while 60% of 
women still had an intact dominant follicle present on day 5 after treatment (vs. 0 in a 
placebo group) 39. The apparent ability of the drug to inhibit follicular rupture after the LH 
surge may explain its continued effectiveness on days 4 and 5 after unprotected sex. 
Dosing in the early luteal phase decreases endometrial thickness, but the clinical 
consequences of this are unknown. 40 
Side Effects and Concerns Related to Use of Oral Emergency Contraception 
Physical Effects. Reported side effects with oral EC use are mild and resolve quickly. 
Women taking combined EC (the Yuzpe regimen) have the highest  rates of nausea 
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regimens, about 20% of women will experience headaches, approximately 14% will 
experience painful menstruation, and approximately 12% will experience nausea.  25 In 
clinical trials of UPA, the most frequently reported side effects were headache, nausea, 
abdominal pain, dysmenorrhea, fatigue, and dizziness. Most were considered “mild or 
moderate” and resolved spontaneously. This side effect profile is very similar to that of a 
single oral dose of levonorgestrel. 
Cycle Length. Bleeding patterns can be altered after use of oral EC, and this seems to 
be dependent on when in the cycle dosing occurs. Use of levonorgestrel EC early in the 
cycle (pre-ovulatory phase) shortens the time to the next period. Some but not all 
studies have shown that levonorgestrel EC taken in the luteal phase can lengthen the 
time to the next period by an average of 2 days. There is some evidence of a slight 
increase in intermenstrual bleeding or spotting after oral levonorgestrel EC, and of 
slightly prolonged bleeding during the next menses after use. 42 Findings are similar for 
UPA use. About 7% of women will have their period a week or so earlier than expected, 
and about 19% will have their period delayed by a week or more. Cycle length of the 
first period after administration may be longer by about 2 days but will return to normal 
by the next month.26,43 
Ongoing Contraception. Fertility returns rapidly after oral EC use, and effective 
contraception should be continued or initiated as soon as possible. While there are no 
data about use of UPA with standard hormonal contraceptives, there are some 
theoretical concerns that UPA, because of its affinity for binding to the progesterone 
receptor, may reduce the contraceptive action of progestin-containing hormonal 
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theoretical concern. According to current practice guidelines from the Faculty of Sexual 
and Reproductive Healthcare Clinical Effectiveness Unit in the United Kingdom (where 
UPA has been available longer than in the United States) 44 , reliable barrier method of 
contraception should be used with subsequent acts of intercourse that occur in the 
same cycle (until the next menses), even if another hormonal contraceptive method is 
begun right after EC dosing.  
Obesity. Concerns have been raised about effects of obesity on hormonal 
contraceptives due to observations about potential alterations in the metabolism of 
some drugs due to obesity and possible reduced effectiveness of contraceptives in 
obese women. Recent secondary analysis of data suggests that the  overall risk of 
pregnancy after oral EC use may be more than threefold greater for obese women 
compared to women with normal body mass index (odds ratio [OR] 3.6; 95% CI, 1.96–
6.53). This differs according to the type of oral EC used: the risk of pregnancy was 
greater for obese women taking levonorgestrel (OR 4.4; 95% CI, 2.05–9.44) than for 
obese women taking UPA (OR 2.6; 95% CI, 0.89–7.00). 45 These findings suggest that 
women in need of EC who have a high body mass index should be offered UPA rather 
than levonorgestrel if they wish an oral treatment, or should be offered an intrauterine 
device for maximum efficacy. However, these observations have not been confirmed, 
and offering any method of EC is preferred to leaving obese women at risk of 
unintended pregnancy.  
Breastfeeding. Lactation is not affected by the use of oral EC. There are no restrictions 
on combined EC or levonorgestrel EC during breastfeeding.46 It should be noted that 
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continue to completely breastfeed, the likelihood of ovulation is low as long as certain 
breastfeeding criteria are met: the woman must be less than 6 months postpartum, not 
have resumed menstruating, and must be exclusively breastfeeding, with no or very 
little supplementation and nursing episodes about every 4 hours, including nighttime. 
Questions arise whether expressing or pumping milk has the same neuroendocrine 
effect on prolactin and other hormones that suppress ovulation as does having the 
infant suckle at the breast. One older study demonstrated striking differences in the 
ability of various breast-pumping methods to produce the necessary prolactin rise in 
breastfeeding mothers, with battery-operated pumps the least effective, and electric 
pulsatile hospital grade pumps the most similar to actual breastfeeding.47 A standard 
global reference states that because manual expression does not elicit the same 
hormonal response as suckling, the likelihood of ovulation suppression will decrease if 
expression or supplementation replaces suckling for more than approximately 10% of 
feeds. 48 Thus, a mother who feeds her infant only breast milk but without nursing at the 
breast may be at risk of ovulation and potential unintended pregnancy; providers should 
educate women about this.  
One study of 12 women compared levonorgestrel concentrations in milk to those 
in plasma. Milk levels were lower (mean milk to plasma ratio 0.28), and the authors 
estimated the infant’s exposure to levonorgestrel as 1.6 micrograms on the day of 
dosing and markedly lower (0.2-0.3 micrograms) on the next 2 days. These authors 
concluded that in order to limit infant exposure to maximum excretion in milk, mothers 
should discontinue nursing for at least 8 hours (but not more than 24 hours).49 However, 
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restrictions on use of EC formulations during breastfeeding.46 No studies have looked at 
the excretion of UPA in human milk, and the drug is not yet included in the US 
guidelines for contraceptive management. Animal studies have shown that it is detected 
in milk of lactating rats. Effects, if any, on an infant are unknown. The manufacturer 
recommends avoiding use of UPA during lactation. 
Drug interactions. Notable adverse interactions with other drugs have not been 
demonstrated with UPA or levonorgestrel, but theoretically any drug or herbal product 
that can induce or inhibit cytochrome p450 liver enzymes may affect plasma 
concentrations of these drugs and should be avoided. Such cautions are typical of those 
that accompany use of hormonal contraceptives. Inducers include: barbiturates, 
bosentan (Tracleer), carbamazepine (Tegretol), felbamate (Felbatol), griseofulvin, 
oxcarbazepine (Trileptal), phenytoin (Dilantin), rifampin, topiramate (Topomax), and St. 
John’s Wort. Inhibitors include itraconazole (Sporanox) or ketoconazole (Nizoral). 
Safety of Oral Emergency Contraception 
Contraindications. There is no evidence that the risks of either combined or 
levonorgestrel-only oral EC outweigh the benefits of use. The US MEC classify both 
combined EC and levonorgestrel-only EC as category 1 or 2 for all conditions. Category 
1 means there are no restrictions on use, and category 2 means that advantages 
generally outweigh any risks of use46. Ulipristal acetate is not yet included in the US or 
WHO MEC. 
The US MEC note that given the low dose and short exposure to these products, 
oral EC or levonorgestrel-only EC can be used by women who might have 
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there is not the same long history of use as there is with the hormones contained in 
contraceptives to allow extrapolation of risks and benefits to be made. However, dosing 
with UPA however is also of very short duration. 
Frequent or continued use. There are no safety concerns with frequent use of 
levonorgestrel-only products; the only possible exception is frequent or repeated use in 
women for whom the US MEC list cautions or contraindications to the use of progestin-
only ongoing contraceptives. 46 This would also apply to repeated use of hormonal 
contraceptives as EC. As previously noted, efforts to develop levonorgestrel-only pills 
as a peri- or postcoital ongoing primary contraceptive were stopped due to 
unacceptable cycle irregularity, but not for safety reasons. A recent Cochrane review of 
the studies of pericoital contraception with levonorgestrel calculated a pooled Pearl 
Index of about 5 pregnancies per 100 woman years 50 when women used EC dosing of 
levonorgestrel as a primary contraceptive. However, many of the studies in this review 
were deemed of suboptimal quality. Trussell has estimated that if a typical woman used 
progestin-only EC for a year, she would have a 20% chance of pregnancy over that 
year. 51 Not only would she enjoy better contraceptive efficacy with a continuous long-
acting contraceptive method, she would also find it less expensive than purchasing 
multiple packages of EC. No data are available regarding repeated use of UPA.  
Pregnancy. In the event of EC failure and subsequent pregnancy, there are no 
conclusive studies of adverse effects of EC use. However, observational data about use 
of oral contraceptives that were inadvertently taken in early pregnancy do not suggest 
concern, and the FDA removed warnings about possible adverse effects of hormonal 
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birth defects in one study that followed more than 300 women who became pregnant 
after taking levonorgestrel EC.53 There is no evidence that using levonorgestrel EC 
increases the risk of ectopic pregnancy 54 
There are few data about UPA, but there is no evidence of adverse effects in the 
small number of women who became pregnant during the clinical trials. There will likely 
be a registry to report possible adverse effects as the drug begins to be prescribed 
more widely. However, if taken as directed, any oral EC provides a short duration of 
drug exposure before embryonic development or even implantation, so adverse effects 
are extremely unlikely. There is no evidence of an increase in the risk of ectopic 
pregnancy after oral UPA use. 
Provision of Oral Emergency Contraception 
Combined Hormonal Products. There is no currently marketed combined EC product. 
These methods are no longer the preferred method of EC, due to the high rates of 
nausea and vomiting associated with their use. However, guidance about how to use 
hormonal contraceptive pills as EC (the Yuzpe regimen) can easily be found on a 
website dedicated to EC (http://ec.princeton.edu/questions/dose.html) and can be used in 
instances where women need EC but local pharmacies do not carry dedicated products.  
Levonorgestrel-only Products. Levonorgestrel is a drug with a long record of safety and 
use in contraceptive products. The single-dose regimen of this drug clearly met FDA 
standards for safety and effectiveness required for over-the-counter (OTC) availability,55 
but efforts to make it available without a prescription met with lengthy delays at the FDA 
and considerable controversy and charges about political agendas. A Citizen’s Petition 
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access finally resulted (in 2006) in FDA approval for OTC access to levonorgestrel EC 
for women aged 18 years and older. Continued legal challenges to the FDA position led 
to a lowering of the age for OTC availability in 2009 to women aged 17 and older. An 
application to remove all age restrictions was filed in 2011 and as of this writing, a 
decision is pending.56 
Over-the-counter approval of EC does not necessarily translate into access for 
many women. A discussion of health care provider refusal to dispense or prescribe 
contraceptives, including EC, is beyond the scope of this paper. However it is important 
for providers to realize that in addition to a number of federal laws that permit health 
care professionals and institutions to refuse to provide care related to abortion and 
sterilization services, 13 states also have laws that permit refusal to provide 
contraceptive services. Ten states allow individual health care providers to refuse to 
provide services related to contraception; 6 states explicitly permit pharmacists to refuse 
to dispense contraceptives, and 5 other states have broad refusal clauses that may 
apply to a variety of health care providers and pharmacists. Nine states also allow 
health care institutions to refuse to provide contraceptive services.57 Even without such 
legislation, individual providers and pharmacists may claim a religious objection to 
providing these services. Before referring women in need of EC to a local pharmacy, 
providers in some areas might be advised to ensure that the pharmacy stocks and will 
dispense the medication.  
 At present women can obtain levonorgestrel EC from a pharmacy without a 
prescription if they can verify they are 17 years of age or older; younger women will 
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younger women will facilitate access and avoid delay in EC dosing. The product may be 
available at lower cost through clinics.  The 1.5 mg dose should be taken as soon as 
possible after, and within 5 days of, unprotected intercourse. 
Ulipristal acetate. Ulipristal acetate is a prescription-only product and should be 
available in pharmacies, although (as is true of all the oral products) demand will predict 
any individual pharmacy’s stock. It should be priced in the general range of the branded 
levonorgestrel product. As a prescription-only drug, it may be covered by insurance 
when the other product is not. Advance prescription will facilitate access and avoid 
delay in taking the medication. There is an online ordering option through a website 
devoted to enabling access to EC (http://ec.princeton.edu/get-ec-now.html). Based on 
data from the clinical trials, the product labeling for UPA states that a single 30 mg oral 
dose of ulipristal acetate should be taken as soon as possible within 120 hours (5 days) 
after unprotected intercourse or a known or suspected contraceptive failure.  
Education about Oral Emergency Contraception 
Women who need EC should be advised that in currently approved doses and 
based on contemporary scientific research, none of these regimens are abortifacients. 
Timing of the dose is especially important, and both combined ECand levonorgestrel-
only EC are most effective if taken within 72 hours of unprotected sex (although they 
remain somewhat less effective until 120 hours). Ulipristal acetate has higher efficacy 
than levonorgestrel for 120 hours after unprotected sex. Women should be counseled 
that they should initiate on ongoing contraceptive method, as repeated use of EC will be 
expensive and increase the rate of side effects, especially bleeding. Because the timing 
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prescription of EC should be done in advance, so a woman has it at hand when she 
needs it.  
DEVICES 
Intrauterine Contraceptives as Emergency Contraception 
The copper-bearing intrauterine device (IUD, ParaGard) is an emergency contraceptive 
option. A properly placed IUD causes an increase in copper, white blood cells, 
prostaglandins, and other chemicals in the uterine and tubal fluid that impairs sperm 
function 58. A distinct advantage of this option over oral EC is that the woman has 
continued effective long-acting contraception. 
 The copper IUD is a long available contraceptive method. There are few absolute 
contraindications to its initiation for ongoing contraception, most relating to current 
pregnancy, uterine or cervical malignancy or infection, and anatomic abnormalities that 
would preclude proper placement 46. It has been studied as an emergency contraceptive 
as well. A prospective multicenter study in 18 family planning clinics in China followed 
the outcomes of 1963 women who had a copper IUD inserted for EC. All had had 
unprotected intercourse within 120 hours; follow-up was at 1 week after expected 
menses, and then at 1, 3, and 12 months following insertion. There were no known 
pregnancies at 3 months. Even if all of the 38 women lost to follow-up prior to the first 
evaluation had become pregnancy, the pregnancy rate would have been between 1% 
and 2%. Of those followed for the full 12 months, the calculated pregnancy rate was 
0.23 pregnancies per 100, far less than the 1% to 3% pregnancy rates calculated for 
various oral EC regimens and  products. 59 The advantages of the copper IUD over oral 
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choosing the copper IUD or oral levonorgestrel. Women selecting the IUD were more 
likely to be using an effective method of contraception (80% vs 50%, P<.001) and less 
likely to have an unplanned pregnancy (2.6% vs 7.0%, P=.04) in the first 6 months after 
presenting  for EC and selecting the IUD than women who selected oral levonorgestrel. 
60  
The levonorgestrel intrauterine system (LNG-IUS, Mirena) has not been evaluated as 
an emergency contraceptive and should not be used for that purpose. 
 
Mechanism of Action of the Copper Intrauterine Device as Emergency 
Contraception 
Although it has been theorized that the presence of the foreign body in the uterus 
acts primarily by preventing implantation of a fertilized egg, studies have demonstrated 
an absence of fertilized, normally dividing ova in the tubes of women using an IUD, 61 
and the noticeable decrease in all pregnancies among IUD users (including ectopic 
pregnancies that implant outside the uterus) supports that the contraceptive effect is not 
related to implantation, but rather to fertilization 61. The WHO Selected Practice 
Recommendations state that an IUD may be inserted up to day 12 of the menstrual 
cycle with no restrictions, and after that only if one is reasonably certain the women is 
not pregnant 62 The IUD can be inserted up to 5 days after ovulation to prevent 
fertilization. Once the fertilized egg is implanted, which occurs 6 to 12 days after 
ovulation, the IUD will not function as EC. Clearly it is difficult to know exactly when a 
woman ovulates, so most experts will say that the copper IUD can be inserted up to 5 
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Side Effects and Concerns related to Intrauterine Device Use for Emergency 
Contraception 
Side effects are the same whether the IUD is placed as an interval insertion for 
contraception or as an emergency contraceptive: counseling the patient about physical 
side effects (cramping) or changes in bleeding patterns would be the same as when 
initiating this method for any woman. There are no concerns about breastfeeding, drug 
interactions, or obesity. 
Active cervical infection is a contraindication to insertion and thus identification of 
asymptomatic STI infection may be a concern; many local practice guidelines mandate 
pre-screening for sexually transmitted infection of the cervix before an IUD can be 
inserted. This creates a barrier to immediate insertion of the IUD, as would be 
imperative for its use as EC. Such testing however can be done at the time of IUD 
insertion, and those women who test positive can be recalled for prompt treatment. In 
one older study, 10% of women with undetected chlamydia at time of insertion 
developed pelvic inflammatory disease (PID), but the risk of PID after insertion was not 
different between those who had a positive chlamydia test and those whose test was 
negative 64. In a recent US study offering the copper IUD as EC, testing for sexually 
transmitted infection was done at the time of insertion. Among 197 women receiving the 
IUD, there were 8 cases of Chlamydia trachomatis discovered (no cases of Neisseria 
gonorrhoeae), and none of the women with chlamydia developed PID  65 If a woman 
receiving an IUD has a positive STI test, she should be treated but the IUD can be left in 
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Many providers worry that IUDs are not as well tolerated in nulliparous women, who 
may comprise a large proportion of women who request EC, or would be expelled more 
often from the nulliparous uterus. A review of 15 studies of women using copper IUDs 
showed that expulsion rates in nulliparous women ranged from 3.3 - 6.2 per 100 
insertions, and removals for bleeding and/or pain in nulliparous women ranged from 9 to 
59 per 100 insertions 66. These data suggest that the vast majority of nulliparous women 
will not expel the IUD and that most will tolerate the device quite well. 
 Another concern expressed by providers who may not have inserted many IUDs 
in nulliparous women is that insertion might be more difficult, and failed insertions more 
common in this group of women. In the Chinese study of copper IUDs for EC, 59 the 
authors reported that 1.5% of women (29/1963) experienced difficult insertion requiring 
local anesthesia; this was not broken down by parity. They also reported that 14% of 
nulliparous women (compared to 5.6% of parous women) required cervical dilation for 
insertion. In another study, done in the United States, there was a 19.6% failed insertion 
rate in nulliparous women. 60 There is no evidence that priming the cervix with 
misoprostol before insertion is effective, and it may delay insertion (for the purpose of 
EC) and increase adverse side effects from absorption of the misoprostol. 67-70 
Safety of the Copper Intrauterine Device as Emergency Contraception 
 The US MEC place the IUD in category 1 (no restrictions on use) or 2 
(advantages generally outweigh risks of use) for most conditions 46. However, the MEC 
rate the use of the copper IUD for EC as a category 3 (risks generally outweigh 
advantages of use) in women who have been raped who might be at high risk for a 
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pregnancy. Nulliparous women 71 and adolescents 72 who desire highly effective 
contraception are candidates for the IUD. The US FDA removed restrictions on copper 
IUD use regarding  parity in 2005, and the both the US and WHO MEC list the device as 
a  category 2 for nulliparous women. There is no evidence that use of an intrauterine 
device will increase the risk of PID once placed. The copper IUD reduces the risk of 
ectopic pregnancy because it is so effective at preventing pregnancy; however, if a 
women becomes pregnant with an IUD in place, the possibility of ectopic implantation 
should be considered. If a woman experiences an IUD failure and wishes to continue 
the pregnancy, the IUD should be removed if possible to reduce the risk of infection. 
Provision of a Copper Intrauterine Device as Emergency Contraception 
Offering the copper IUD is the first step to having women consider it as an EC 
option. A study in Utah asked women aged 18 to 45 years presenting for EC at 4 family 
planning clinics in the state whether they would be willing to get a long acting reversible 
contraceptive method for EC instead of pills; 34% expressed an interest, and 37% of 
these were still interested when they learned that it was an intrauterine device being 
proposed. Overall 13% of those surveyed would have been willing to have an IUD for 
EC even with additional waiting time and undergoing a pelvic examination and insertion 
procedure 63  
If an IUD is offered, the woman should be medically eligible according to practice 
standards set by the US MEC 46. A good sexual and menstrual history is important to 
rule out the possibility of pregnancy from previous acts of intercourse. A highly sensitive 
urine pregnancy test will help to rule out an existing early pregnancy. There must be a 
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be developed to facilitate immediate insertion. The device generally can be inserted 
within 5 days of unprotected intercourse. 
 
SUMMARY AND CONCLUSION 
 Emergency contraception is an important means of preventing unintended 
pregnancy. The most comprehensive and current source of information about EC for 
patients and clinicians is the EC Web site run by the Office of Population Research at 
Princeton University and the Association of Reproductive Health Professionals. This 
Web site can be accessed at www.not-2-late.com. 
 Clinicians should ensure that women are aware of their EC options and be 
prepared to provide such options promptly should a woman request it. Assessment of 
need, risk, and identifying the woman’s plans for ongoing contraception will allow the 
provider in assisting a woman make appropriate decisions about her EC options. 
Availability of oral options in one’s local community should be evaluated, and women 
referred to pharmacies that have oral options in stock and do not place restrictions on 
dispensing them. Providers who are inexperienced in the provision of the IUD option 
should identify colleagues to whom woman can be promptly referred. Removing barriers 
to EC access and use will provide women with a last chance to prevent pregnancy after 
unprotected intercourse. 
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Abbreviations: MEC, Medical Eligibility Criteria for Contraceptive Use; STI, sexually transmitted infection  
Sources: Centers for Disease Control and Prevention 46 , Food and Drug Administration 22 ,Glasier 45 ,Trussell51 , World Health Organization 62 , Wu 
59 ,  
a US MEC Categories: 
Category 1: a condition for which there is no restriction 
Category 2: a condition for which the advantages of using the method generally outweigh the theoretical or proven risks 
Category 3: a condition for which the theoretical or proven risks usually outweigh the advantages of using the method 
Category 4: a condition that represents an unacceptable health risk if the contraceptive method is used. 
b A single dose has been shown to be as effective as 2 doses, although some package labeling continues to state it should be taken in 2 doses. 
c Rates taken from clinical trials that compared levonorgestrel and ulipristal acetate and calculated actual risk, not relative risk. 
d This rate was taken from a single-arm trial that evaluated the effectiveness of ulipristal acetate beyond 72 hours. 
e These regimens are not the first choice, due to associated rates of nausea and vomiting. If these are the only option available for a woman, the 
number of pills and dosing from 19 different branded combined oral contraceptive products is available from the Princeton University Office of 
Population Research and Association of Reproductive Health Professionals and can be accessed at 
http://ec.princeton.edu/questions/dose.html.) 
 
f No studies have evaluated effectiveness beyond 72 hours. 
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